Health Trials

DESTINY-PANTUMOUR04

ConditionsAdenocarcinoma (NOS)Anal CancerBladder CancerCervical CancerEndometrial CancerEsophageal CancerGall Bladder CancerGastrointestinal Stromal TumourHead and Neck CancerLiver CancerMelanomaMouth CancerNasopharangeal CancerNeuroendocrine, Gastrointestinal CancerOvarian CancerPancreatic CancerProstate CancerRenal Cell CarcinomaSalivary Gland CancerSarcomaSmall Cell Lung CancerTesticular CancerThroat CancerThyroid CancerUrethral CancerVaginal CancerVulvar Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-130
SponsorAstraZeneca

About this trial

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Eligibility criteria

Qualifiers

Adults aged ≥18 years

Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);

A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;

HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;

Disqualifiers

Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;

Prior T-DXd therapy;

Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.

Patient is participating in a clinical trial at time of enrolment

Trial design

Treatments tested in this trial

  • Trastuzumab deruxtecan

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators

AstraZeneca

Lead sponsor

Source ClinicalTrials.gov